PEG-MGF (PEGylated Mechano Growth Factor)
Fat LossPEGylated IGF-1 splice variant / researchExperimental
PEGylated mechano-growth-factor (IGF-1Ec) analog sold for muscle-repair research. Not FDA-approved. WADA S2 (IGF / MGF).
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- ≈8–10 kDa (PEG dependent)
- Half-life
- Extended vs native MGF; no validated human PK
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- IGF-1 receptorMuscle satellite cells (proposed)
Overview
PEGylated mechano-growth-factor (IGF-1Ec) analog sold for muscle-repair research. Not FDA-approved. WADA S2 (IGF / MGF).
Protocol
- Dosage Range
- Not established
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
MGF is an IGF-1 splice variant induced by mechanical load; PEGylation is intended to extend circulating half-life of a research analog.
Targets
IGF-1 receptorMuscle satellite cells (proposed)
Studies
- Mechano growth factor review— Journal/year not available
Benefits
Load-induced IGF splice-variant research
Potential Side Effects
- Unknown PEGylated-peptide AEs
References
- PMID 16581882External link · Year —
- WADA Prohibited List 2026External link · Year —